{"organizations": [], "uuid": "880dedc8db8c7164df4d40c89ab277d6d34e4b3a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-apricus-biosciences-announces-sche/brief-apricus-biosciences-announces-scheduling-of-vitaros-end-of-review-meeting-with-fda-idUSFWN1R80DO", "country": "US", "domain_rank": 408, "title": "BRIEF-Apricus Biosciences Announces Scheduling Of Vitaros End-Of-Review Meeting With FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-26T14:21:00.000+03:00", "replies_count": 0, "uuid": "880dedc8db8c7164df4d40c89ab277d6d34e4b3a"}, "author": "", "url": "https://www.reuters.com/article/brief-apricus-biosciences-announces-sche/brief-apricus-biosciences-announces-scheduling-of-vitaros-end-of-review-meeting-with-fda-idUSFWN1R80DO", "ord_in_thread": 0, "title": "BRIEF-Apricus Biosciences Announces Scheduling Of Vitaros End-Of-Review Meeting With FDA", "locations": [], "entities": {"persons": [{"name": "vitaros end-of-rev", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "brief-apricus biosciences", "sentiment": "negative"}, {"name": "fda reuters staff   apricus biosciences inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "apricus biosciences inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 21 AM / Updated 13 minutes ago BRIEF-Apricus Biosciences Announces Scheduling Of Vitaros End-Of-Review Meeting With FDA Reuters Staff   Apricus Biosciences Inc: * APRICUS BIOSCIENCES ANNOUNCES SCHEDULING OF VITAROSâ„¢ END-OF-REVIEW MEETING WITH FDA * APRICUS BIOSCIENCES INC - END-OF-REVIEW MEETING WITH U.S. FDA NOW SCHEDULED TO BE HELD ON APRIL 12 * APRICUS BIOSCIENCES INC - INTEND TO FURTHER CLARIFY DEFICIENCIES RAISED IN CRL AND INFORMATION THAT MAY BE NEEDED TO RESOLVE SUCH DEFICIENCIE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-26T14:21:00.000+03:00", "crawled": "2018-03-26T14:43:22.018+03:00", "highlightTitle": ""}